Media
June 16, 2026
Medical cannabis: the driving force behind Canopy Growth’s recovery
By Aurélien BERNARD
Canadian cannabis producer Canopy Growth announced a significant improvement in its financial results for the fourth quarter of fiscal year 2026, driven by strong growth in both the medical cannabis sector and its international operations. These results suggest that the restructuring efforts the company has been undertaking for several years may finally be starting to pay off.
June 1, 2026
New Canopy Growth products hit the German market
Canopy Growth Corp. announced the relaunch of the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis Corp. (MTL), a wholly-owned subsidiary of the company....
April 27, 2026
Canopy Growth’s New Budget Cannabis Brand Focuses on High Potency
Canopy Growth today announced Deelish ("DEE-LISH"), a new cannabis brand "built for the everyday consumer with an everyday price." Deelish enters the market with flower testing at 27%-33% THC and pre-rolls at 26%-32% THC. The brand will rotate its genetic lineup regularly, giving consumers access to a range of cultivars over time....
March 16, 2026
Canopy Growth completes acquisition of MTL Cannabis
Canopy Growth Corporation has completed its previously announced arrangement to acquire MTL Cannabis Corp. This deal involved Canopy acquiring all of the issued and outstanding common shares of MTL, with the combined company establishing Canada’s leading medical cannabis platform by revenue.